What side effects are most common with Prolia (denosumab)?
Prolia can cause side effects tied to its effect on bone turnover, along with effects that show up in bone/lower calcium levels. The main ones patients ask about are:
- Low calcium levels (hypocalcemia), especially in people with kidney problems
- Back, arm, or leg pain
- Pain in the arms and legs
- Serious skin reactions can occur, though they are less common
- Infections can occur, including skin infections
- Musculoskeletal pain can occur, including joint pain
What side effects are most common with Reclast (zoledronic acid)?
Reclast (zoledronic acid) side effects often look like a short “flu-like” reaction after the infusion, plus digestive and musculoskeletal effects. Commonly reported effects include:
- Flu-like symptoms after the infusion (fever, chills, body aches), especially after the first dose
- Headache
- Bone, joint, or muscle pain
- Nausea
- Fatigue
- Reactions related to the infusion
How do the side-effect profiles compare?
The biggest practical differences patients and clinicians weigh are:
- Timing: Reclast commonly causes acute, short-term flu-like symptoms soon after an infusion; Prolia side effects are not usually described as infusion-day flares.
- Calcium risk: Both therapies can lower calcium levels, but hypocalcemia is a particular concern with Prolia, especially in people with reduced kidney function.
- Pain patterns: Both can cause musculoskeletal pain, but Reclast’s first-dose “sick” feeling is a frequent talking point.
What side effects should people with kidney disease worry about?
Kidney function changes the risk picture for calcium balance:
- With Prolia, hypocalcemia risk is higher when kidney function is impaired, so calcium and vitamin D repletion before treatment matters.
- With Reclast, kidney safety is a core issue for zoledronic acid because it’s cleared through the kidneys, so clinicians typically check kidney function before each infusion.
Are there serious risks with either medication?
Both drugs carry rare but serious risks clinicians monitor for in osteoporosis treatment:
- Prolia: osteonecrosis of the jaw (ONJ) and atypical femur fractures are known class risks; hypocalcemia can also be serious.
- Reclast: ONJ and atypical femur fractures are also known class risks; kidney injury is a key safety consideration with zoledronic acid.
Can stopping Prolia cause problems?
Yes. Stopping Prolia is associated with a rebound increase in bone turnover that can lead to loss of bone density and, in some patients, higher fracture risk. If treatment is stopped, doctors usually plan a transition to another osteoporosis medicine to reduce that risk.
How does choosing between them affect side effects and patient comfort?
- People who strongly prefer avoiding infusion-day flu-like symptoms often find Prolia more comfortable from a “day after dosing” standpoint.
- People who are comfortable with an annual infusion and want a treatment schedule that does not involve frequent injections may prefer Reclast, but they should plan for possible short-term flu-like effects after the first dose.
Where can I check detailed safety and labeling?
For patent and product-background research tied to these therapies, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com